Clinical Trials
21 trialsNCT04984837 2026-06-04
Study of Lacutamab in Peripheral T-cell Lymphoma
The Lymphoma Academic Research Organisation
Phase 2 Active not recruiting
NCT06131801 2026-06-04
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Children's Hospital Medical Center, Cincinnati
Recruiting
NCT07624838 2026-06-03
Real-life Experience of Brentuximab Vedotin Plus CHP as First-line Treatment of CD30+ Peripheral T-cell Lymphomas in Spain
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Recruiting
NCT07615283 2026-05-29
Adebrelimab Combined With SHR2554 in Relapsed/Refractory PTCL and NK/T-Cell Lymphoma
Sun Yat-sen University
Phase 1/2 Not yet recruiting
NCT06508463 2026-05-28
Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma
Mayo Clinic
Phase 1 Recruiting
NCT02362997 2026-05-18
Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL
Dana-Farber Cancer Institute
Phase 2 Completed
NCT05976997 2026-05-18
Prospective, Single Arm, Single Center Study of Duvelisib Combined With Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma (PTCL)
Huazhong University of Science and Technology
Phase 2 Recruiting
NCT03927105 2026-05-07
Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT03547700 2026-05-06
Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL)
University of Michigan Rogel Cancer Center
Phase 1/2 Terminated
NCT05377827 2026-05-06
Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies
Washington University School of Medicine
Phase 1 Active not recruiting
NCT05182957 2026-05-01
Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma
The First Affiliated Hospital of Soochow University
Phase 2 Recruiting
NCT06362148 2026-05-01
CIRCULATE
University of Aarhus
Active not recruiting
NCT07535762 2026-04-17
Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Untreated Peripheral T-Cell Lymphoma
Shanghai Jiao Tong University School of Medicine
Phase 2 Not yet recruiting
NCT07356245 2026-04-15
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 2 Recruiting
NCT06176690 2026-04-13
CABAL2
Baylor College of Medicine
Phase 1 Recruiting
NCT04512534 2026-04-02
Sincerely20
Fudan University
Phase 2 Recruiting
NCT06692452 2026-04-01
Tazemetostat Plus CHOP in 1L T-cell Lymphoma
Dana-Farber Cancer Institute
Phase 2 Withdrawn
NCT07300514 2026-03-31
T-START-M1
Fudan University
Phase 3 Recruiting
NCT06519526 2026-03-24
Exploratory Clinical Study of SHR-0302 and SHR-2554 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma
Fudan University
Phase 2 Recruiting
NCT07270861 2026-03-24
Real-world Outcomes of Peripheral T-cell Lymphoma: A Multicenter Retrospective and Prospective Cohort Study
Fudan University
Recruiting
NCT07164560 2026-03-17
Exploratory Study of Umbilical Cord Blood-Derived CAR-NK Cell Therapy Targeting TRBC1/2 for Relapsed/Refractory T-Cell Lymphoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 1 Recruiting